• 1
    Kucharzik T, Maaser C, Lugering A, et al. Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm Bowel Dis. 2006; 11: 10681083.
  • 2
    Kovacs EJ, DiPietro LA. Fibrogenic cytokines and connective tissue production. FASEB J. 1994; 11: 854861.
  • 3
    Baragi VM, Qiu L, Gunja-Smith Z, et al. Role of metalloproteinases in the development and healing of acetic acid-induced gastric ulcer in rats. Scand J Gastroenterol. 1997; 5: 419426.
  • 4
    Arthur MJ. Fibrosis and altered matrix degradation. Digestion. 1998; 4: 376380.
  • 5
    Bailey CJ, Hembry RM, Alexander A, et al. Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine. J Clin Pathol. 1994; 2: 113116.
  • 6
    Baugh MD, Perry MJ, Hollander AP, et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology. 1999; 4: 814822.
  • 7
    Salmela MT, MacDonald TT, Black D, et al. Upregulation of matrix metalloproteinases in a model of T cell mediated tissue injury in the gut: analysis by gene array and in situ hybridisation. Gut. 2002; 4: 540547.
  • 8
    Vaalamo M, Karjalainen-Lindsberg ML, Puolakkainen P, et al. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol. 1998; 4: 10051014.
  • 9
    Vizoso FJ, Gonzalez LO, Corte MD, et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer. 2007; 6: 903911.
  • 10
    von Lampe B, Barthel B, Coupland SE, et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut. 2000; 1: 6373.
  • 11
    Warnaar N, Hofker HS, Maathuis MH, et al. Matrix metalloproteinases as profibrotic factors in terminal ileum in Crohn's disease. Inflamm Bowel Dis. 2006; 9: 863869.
  • 12
    Di Sebastiano P, di Mola FF, Artese L, et al. Beneficial effects of Batimastat (BB-94), a matrix metalloproteinase inhibitor, in rat experimental colitis. Digestion. 2001; 4: 234239.
  • 13
    Pender SL, Fell JM, Chamow SM, et al. A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol. 1998; 8: 40984103.
  • 14
    Rosemar A, Ivarsson ML, Borjesson L, et al. Increased concentration of tissue-degrading matrix metalloproteinases and their inhibitor in complicated diverticular disease. Scand J Gastroenterol. 2007; 2: 215220.
  • 15
    Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res. 2000; 12: 48234830.
  • 16
    Demers M, Couillard J, Belanger S, et al. New roles for matrix metalloproteinases in metastasis. Crit Rev Immunol. 2005; 6: 493523.
  • 17
    Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 3: 161174.
  • 18
    Noe V, Fingleton B, Jacobs K, et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci. 2001;( Pt 1): 111118.
  • 19
    Turk V, Kos J, Turk B. Cysteine cathepsins (proteases)–on the main stage of cancer? Cancer Cell. 2004; 5: 409410.
  • 20
    Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest. 1999; 9: 12371241.
  • 21
    Cornelius LA, Nehring LC, Harding E, et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol. 1998; 12: 68456852.
  • 22
    Lambert E, Dasse E, Haye B, et al. TIMPs as multifacial proteins. Crit Rev Oncol Hematol. 2004; 3: 187198.
  • 23
    Parker RL, Huntsman DG, Lesack DW, et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol. 2002; 5: 723728.
  • 24
    Shi SR, Liu C, Balgley BM, et al. Protein extraction from formalin-fixed, paraffin-embedded tissue sections: quality evaluation by mass spectrometry. J Histochem Cytochem. 2006; 6: 739743.
  • 25
    Jones JL, Walker RA. Control of matrix metalloproteinase activity in cancer. J Pathol. 1997; 4: 377379.
  • 26
    Garg P, Rojas M, Ravi A, et al. Selective ablation of matrix metalloproteinase-2 exacerbates experimental colitis: contrasting role of gelatinases in the pathogenesis of colitis. J Immunol. 2006; 6: 41034112.
  • 27
    Medina C, Radomski MW. Role of matrix metalloproteinases in intestinal inflammation. J Pharmacol Exp Ther. 2006; 3: 933938.
  • 28
    Naito Y, Yoshikawa T. Role of matrix metalloproteinases in inflammatory bowel disease. Mol Aspects Med. 2005; 4,5: 379390.
  • 29
    Ravi A, Garg P, Sitaraman SV. Matrix metalloproteinases in inflammatory bowel disease: boon or a bane? Inflamm Bowel Dis. 2007; 1: 97107.
  • 30
    Ala-aho R, Kahari VM. Collagenases in cancer. Biochimie. 2005; 3,4: 273286.
  • 31
    Mimura T, Bateman AC, Lee RL, et al. Up-regulation of collagen and tissue inhibitors of matrix metalloproteinase in colonic diverticular disease. Dis Colon Rectum. 2004; 3: 371378; discussion 378–379.
  • 32
    Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol. 2002; 3: 207214.
  • 33
    Ramamurthy NS, Xu JW, Bird J, et al. Inhibition of alveolar bone loss by matrix metalloproteinase inhibitors in experimental periodontal disease. J Periodontal Res. 2002; 1: 17.
  • 34
    McKaig BC, McWilliams D, Watson SA, et al. Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol. 2003; 4: 13551360.
  • 35
    Kirkegaard T, Hansen A, Bruun E, et al. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut. 2004; 5: 701709.
  • 36
    Makitalo L, Sipponen T, Karkkainen P, et al. Changes in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinases (TIMP) expression profile in Crohn's disease after immunosuppressive treatment correlate with histological score and calprotectin values. Int J Colorectal Dis. 2009; 10: 11571167.
  • 37
    Schuppan D, Hahn EG. MMPs in the gut: inflammation hits the matrix. Gut. 2000; 1: 1214.
  • 38
    Meijer MJ, Mieremet-Ooms MA, van Duijn W, et al. Effect of the anti-tumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease. Inflamm Bowel Dis. 2007; 2: 200210.